# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wedbush analyst Robert Driscoll reiterates Aprea Therapeutics (NASDAQ:APRE) with a Outperform and maintains $11 price target.
HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...
Features Medicinal Chemistry Expert Joseph Vacca And University Of Pennsylvania's Eric J. Brown Discussing Preclinical Find...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose ...